Quoin Pharmaceuticals Posts $0.97 Q3 GAAP Loss Per ADS
Photo: TokenPost
Quoin Pharmaceuticals Ltd. posted a third-quarter 2026 GAAP loss of $0.97 per American depositary share (ADS), as its net loss and operating expenses both increased from a year earlier. Net loss reached $4.87 million, compared with $3.95 million in the year-ago quarter. Operating expenses rose to $4.92 million from $4.02 million. Research and development costs were $2.66 million, up from $2.28 million. General and administrative expenses increased to $2.27 million from $1.74 million. Quoin had $10.1 million in cash and cash equivalents and $23.1 million in investments as of Sept. 30.
Source: TokenPost
